KEI submitted a post-hearing submission to the USTR for the Special 301 on behalf of itself and twelve other international NGOs and academic institutions condemning recent pressures on Colombia’s legal and regulatory measures to increase access to affordable medicines, including… Continue Reading
This is an update to a 2007 report regarding a district court decision in the Innogenetics v. Abbott case here, regarding Abbott’s infringement of Innogenetics’s patents for HCV genotyping. The previous blog discusses the ruling at the district court level… Continue Reading
Representative Ro Khanna (D-CA-17) was joined by 17 other members of Congress in calling upon Department of Health and Human Services Secretary Alex Azar to issue a compulsory license on patents for medications to treat hepatitis C, by exercising 28… Continue Reading
Brazil 1990-2000 Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May 13-16,1997, 1997-05-16 2005 U.S. DoS Cable: U.S. PHARMA FIRMS THREATENED WITH LICENSING (Brazil), June 3, 2005. U.S. DoS… Continue Reading
The Cámara de Diputados of the Chilean Congress has overwhelmingly passed a resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. The resolution, Number… Continue Reading
For more information, contact: (U.S.) Andrew Goldman, KEI: firstname.lastname@example.org or +1 (202) 332-2670 (Chile) Luis Villaroel, Innovarte: email@example.com +56 9 9827 9673 Chile FAQ What is happening in Chile with regard to HCV medicines and Xtandi, for prostate cancer? In… Continue Reading
On Wednesday, July 22, 2015, the Senate Veterans Committee held a mark-up to consider several bills. During the mark-up, Senator Sanders offered an amendment, attached below, that would create a compulsory license mechanism in the Department of Veterans Affairs, for patents on medical inventions. (See amendment text below). The motivation for the amendment was a crisis in the VA involving access to drugs for the hepatitis C virus (HCV).
Attached is the text of a letter sent by Senator Bernie Sanders to Robert A. McDonald, the Secretary, U.S. Department of Veterans Affairs, asking the Secretary “to use your authority as Secretary of Veterans Affairs to break the patents on Hepatitis C medications for the treatment of veterans suffering with the disease.”
On March 18, 2015, KEI, KEI Europe, and Essential Inventions submitted proposals for global voluntary licences for all patents necessary for hepatitis C (HCV) medicines to five drug companies — AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.